ProfileGDS5678 / 1437546_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 90% 87% 88% 88% 84% 86% 87% 82% 88% 87% 87% 84% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.342785
GSM967853U87-EV human glioblastoma xenograft - Control 27.1689590
GSM967854U87-EV human glioblastoma xenograft - Control 36.6298787
GSM967855U87-EV human glioblastoma xenograft - Control 47.0840188
GSM967856U87-EV human glioblastoma xenograft - Control 56.8356188
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9535784
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2923986
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6466587
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9567782
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8456688
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6522487
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8152487
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2484784
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.4718986